by Alan Louette | Oct 10, 2024 | Press Release
First clinical data of VO659 demonstrated 28% mean reduction in CSF mutant HTT at day 85 in HD patients in 40 mg dose cohort with an effect after the first dose No sustained increase in CSF neurofilament light chain (Nf-L) protein observed through day 85 VO659 is...
by VICO Therapeutics | Jan 5, 2024 | Press Release
Funding supports ongoing Phase 1/2a clinical trial evaluating VO659 in patients with spinocerebellar ataxia type 3 and type 1 and Huntington’s disease Financing led by Ackermans & van Haaren along with Droia Ventures, EQT Life Sciences and Kurma Partners with...
by VICO Therapeutics | Apr 3, 2023 | Press Release
VO659 is the only clinical-stage candidate targeting the CAG repeat expansion that causes these diseasesVO659 was designed to preferentially reduce mutant HTT and spare wild-type HTTPhase 1/2a basket trial design and preclinical VO659 data to be presented at CHDI...
by VICO Therapeutics | Oct 3, 2022 | Management, Press Release
Dr. Schobel joins Vico from Roche where he was the clinical science leader for tominersen being developed for Huntington’s disease LEIDEN, Netherlands, October 3, 2022 – Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the...
by VICO Therapeutics | Aug 4, 2022 | Management, Press Release
LEIDEN, Netherlands, Aug. 1, 2022 /PRNewswire/ — Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of Micah Mackison as Chief Executive Officer. Mr. Mackison brings significant biotechnology and pharmaceutical...
by VICO Therapeutics | Jul 29, 2021 | Press Release
Leiden, The Netherlands, 29 July 2021 – VICO Therapeutics,a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan...
